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SUMMARY
Background. The concept of rational polytherapy implies using a combination of antiepileptic drugs with 
synergistic effect, which in turn, may result in additive or reduced toxicity. This concept is not consensu-
ally accepted.
Aim. To present evidence in favour and against rational polytherapy.
Methods. Narrative literature review on PubMed and Medline databases using the following terms: epi-
lepsy treatment, rational therapy/polytherapy, supraadditive treatment, drug-resistant epilepsy treat-
ment. Cited references within selected articles were also evaluated.
Results. Against rational therapy is the evidence of clinical efficacy of the use of antiepileptic drugs with 
the same mechanism of action and without increased side-effects. Rational therapy may fail because 
while the addition of one antiepileptic drug to others with the same or different mechanisms of action 
leads to additive therapeutic efficacy, it also leads to more side effects. The evidence for the robust, 
unique, true synergism found between valproate and lamotrigine is questionable because the two drugs 
together may lead to complex pharmacokinetic interactions jeopardizing a consistent interpretation of 
the data. Data from studies with antiepileptic drugs with multiple mechanisms of action may be ques-
tionable because the same mechanism of action might not be responsible for drug efficacy or toxicity in 
different patients. Favouring rational therapy is the evidence that genetic animal models of seizures and 
drug-related neurotoxicity are ideal to evaluate the efficacy and toxicity of drug combinations, and that 
the most successful experimental combination of two antiepileptic drugs would be the one with a single 
mechanism of action and the other with a multiple mechanism of action.
Conclusion. Rational therapy is a sub-optimal, but worth being attempted strategy for the use of antiepi-
leptic drugs in combination.
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BACKGROUND
Until the seventies and eighties of the last century, the 
pharmacological treatment of epilepsy was based on 
polytherapy and commercially available medications 
generally combining a barbiturate, phenobarbital (PB), 
with phenytoin (PHT). Then, the strategy changed and 
the regimen of monotherapy was established for the 
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treatment of epilepsy (Reynolds et al., 1976; Reynolds 
and Shorvon, 1981). During this period, whenever pol-
ytherapy was required, the rationale for choosing two 
antiepileptic drugs (AEDs) was based on the avoidance 
of combined pharmacodynamic or pharmacokinetic 
side effects (French and Faught, 2009).
In the ninth decade of the twentieth century, the so-
called second-generation antiepileptic drugs (SGAEDs) 
started being commercialized. They had the advantag-
es of better pharmacokinetic and pharmacodynamic 
profiles, less side effects and fewer drug interactions 
when compared with their first generation counter-
parts. Furthermore, several of them had novel mecha-
nisms of action (MoA).
These properties of the SGAEDs lead to a re-eval-
uation of the polytherapy strategy and to new meth-
ods of choosing a second (or more) AED. This new ap-
proach was called rational polytherapy (RP) (Ferrendel-
li, 1995; Anonimous, 1995). In essence, RP consists of 
selecting combinations of AEDs that result in a great-
er clinical efficacy (additive or synergistic effect) com-
pared to the one obtained by chance, but with additive 
or even infraadditive, toxicity. In other words, RP was 
defined as the association of different AEDs with un-
related MoAs, without complex pharmacokinetics in-
teractions, with separate adverse events, and combined 
in moderate doses to produce major/synergistic effect 
(Mawer and Pleuvry, 1995). This novel idea of using AE-
Ds with unrelated MoA arose from the growing body 
of evidence that combination of AEDs with different 
MoA would be an effective strategy to treat refractory 
epilepsies (RE) (Brodie and Sills, 2011).
The synergistic effect mentioned above has been well 
described (Mawer and Pleuvry, 1995). In short, when-
ever a similar dose of two AEDs is used the same ef-
fect will be obtained. If, however, a similar clinical ef-
fect is reached using a lower dose of one or both of the 
AEDs it is referred to as a synergistic effect. This is ac-
complished by using AEDs with fewer side effects and 
drug interactions and, preferentially, with different 
MoAs (Barker-Haliski et al., 2014) (For reviewing the 
MoAs of AEDs, refer to Brodie, 2016).
The synergistic effect is an interesting concept but, 
unfortunately, it has never been clearly demonstrated in 
clinical practice. Indeed, studies performed in patients 
on polytherapy showed that suppraadditive adverse ef-
fects due to phramacodynamic interactions were more 
likely to occur when AEDs displayed the same MoAs 
(Barker-Haliski et al., 2014).
The ideal combination of AEDs in RP should include 
drugs with unique and different MoA, or one drug with 
a unique and the other with several MoAs (Brodie and 
Sills, 2011). Hence, RP may be accomplished by using 
the SGAEDs (French and Faught, 2009).
However, this new form of polytherapy has not been 
universally accepted given the absence, in general, of 
robust evidence of its efficacy (Barker-Haliski et al., 
2014; Brodie and Sills, 2011).
AIM
In this article, we aim to compreensivelly review this 
topic presenting the evidence in favour and against the 
use of RP for the daily management of RE.
METHODS
A critical analysis of medical literature on the issue was 
conducted through an independent narrative literature 
review on PubMed and Medline databases. We select-
ed articles in Portuguese, English, French and Span-
ish, with no restriction to the date of publication. The 
search was performed using combinations of the fol-
lowing terms: epilepsy treatment, rational therapy/pol-
ytherapy, supraadditive treatment, drug-resistant epi-
lepsy treatment. Cited references within selected arti-
cles were also evaluated.
RESULTS
Rational polytherapy. Myth?
A clinical significant “rational” combination of AEDs 
should provide suppraadditive, synergistic anticon-
vulsivant effects and additive/infraadditive toxicity. 
Indeed, when the suppraadditive anticonvulsivant ef-
fects are associated with a high toxicity (whenever ad-
verse effects of a synergistic combination also leads to 
suppraadditive summation) the protective index (de-
fined as a comparison of the amount of a drug causing 
a therapeutic effect to the one producing toxicity, and 
determined as the ratio given by the toxic dose divid-
ed by the therapeutic dose) may be unchanged or even 
reduced. Hence, high values of the protective index are 
preferable to low values, given that a higher dose of the 
AED would have to be taken to reach the toxic thresh-
old compared with the dose to obtain a therapeutic ef-
fect (Brigo et al., 2013).
The concept of “drug loading” (initial higher dose 
of a drug that is given at the beginning of a course of 
treatment before dropping down to a lower mainte-
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nance dose (equivalent dosages i.e., equal drug loads) 
may also bring some insight into whether the increased 
effectiveness of a combination of AEDs (either with the 
same or different MoAs) is due to an improvement in 
efficacy or in tolerability. A robust study looking at the 
monotherapy versus polytherapy focussing primarily 
on tolerability did not show evidence of differences in 
overall efficacy and neurotoxicity between the two re-
gimes in which AEDs were started in equal dose loads 
(Deckers et al., 2001).
Clinical efficacy has been demonstrated by the use of 
AEDs with the same MoA (Stephen and Brodie, 2002). 
However, undesirable and avoidable neurotoxic associa-
tions may occur or emerge in patients treated with com-
binations of AEDs with the same MoAs, as between so-
dium blockers such as PHT, carbamazepine (CBZ), la-
motrigine (LTG), or oxcarbazepine (OXC) (Brodie and 
Yuen, 1997), although results were conflicting. Indeed, 
an OXC placebo-controlled, dose ranging trial (Barcs 
et al., 2000) showed a dose-dependent increase in the 
incidence of premature discontinuations due to AEDs 
regardless of concomitant AED use. Different MoA for 
OXC and CBZ were also proposed in this study due to 
the fact that a large number of patients were already on 
CBZ and benefited with the addition of OXC. Anoth-
er more recent, retrospective and observational study 
with lacosamide (LCM) as adjunctive therapy in uncon-
trolled epilepsy (Flores et al., 2012) showed that add-
ing LCM to drugs acting on the sodium channel was 
in general, but not statistically significant, more effica-
cious compared to adding it to AEs with other MoAs.
From the early experience with SGAEDs, it became 
clear that the majority of the patients could be con-
trolled by monotherapy, with only less than 4% of them 
requiring polytherapy (Kwan and Brodie, 2000a; Bro-
die, 2013). It is uncertain whether this small percent-
age of success could be attributed to a synergistic ef-
fect or to an additive effect of the multiple drugs used.
 Previous attempts to prove a synergistic effect in 
more limited situations have not shown consisting suc-
cess (Kwan and Brodie, 2000a; Besag et al. 1998). Ac-
cording to the work of Kwan and Brodie (2000a), none 
of the 11 patients who received add-on treatment after 
a second drug became seizure-free. In the study of Bes-
ag et al. (1998), the authors concluded that toxicity is 
more likely to occur when LTG is added to CBZ. A re-
duction of the dose of CBZ usually reduces the toxicity, 
allowing the dose of LTG to be increased to achieve its 
maximum effect. Isobolographic analysis from a sei-
zure model in mice also showed lack of synergism be-
tween LCM with VPA or PHT (Brigo et al., 2013). Other 
combinations that revealed no synergism include those 
between topiramate (TPM) or sodium valproate (VPA) 
with PHT or CBZ (St Louis, 2009).
 Moreover, the results of pivotal studies to commer-
cialise some of the SGAEDs, namely OXC or eslicarbaz-
epine acetate (ESL), failed to prove the principle of RP. 
In these studies, the addition of CBZ to another AEDs 
with the same or different MoA, lead to additive effica-
cy and more side effects (Halasz et al., 2010). In a well-
designed, multicentre, parallel-group, open label study 
looking at this problem, patients with partial epilepsy 
not controlled by a single AED or sequential AED mon-
otherapy were randomised to alternative monotherapy 
or to adjunctive therapy. However, again, there was no 
significant difference between the two groups regard-
ing seizure freedom or retention rate (Beghi et al., 2003).
By looking at the problem in a different way, we 
might assume that using AEDs with multiple MoAs 
would be more efficient than using AEDs with only one 
known MoA. However, recent data on the use of zon-
isamide (ZNS) versus CBZ (Baulac et al., 2012), or the 
older study comparing VPA and CBZ (Mattson et al., 
1992), showed that CBZ was as effective, or even more 
effective, than the AEDs with multiple MoAs.
The only evidence for a possible synergism between 
two AEDs was established for VPA and LTG (Brodie 
and Yuen, 1997; Pisani et al., 1999), but these two drugs 
lead to complex pharmacokinetics interactions that 
may jeopardize a consistent interpretation. Further-
more, the study of Pisani et al. (1999) had a small sam-
ple of 20 patients and changes in seizure frequency were 
analysed descriptively, without formal statistical anal-
ysis. Another study (Moeller et al., 2009) with similar 
limitations due to its retrospective design in which pa-
tients were prescribed LTG plus VPA at the discretion 
of the epileptologist and not in a randomized way, this 
combination proved to be clinically effective. Further-
more, the adverse effects that occurred were resolved 
by decreasing the dosage of one of the drugs without 
seizure exacerbation.
 Experiments in the preclinical phase have not con-
formed to the literature on synergistic clinical effica-
cy. A review of more than one hundred studies eval-
uating 536 experimental drug interactions concluded 
that no single combination of AEDs consistently dis-
played true synergism (Jonker et al., 2007).
Several reviews have addressed this issue, with the 
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overall conclusion being that RP “remains speculative 
concerning better efficacy based on the use of AEDs 
with differing MoAs” (Ben-Menachem, 2014), and that 
“experimental and clinical evidence in support of it is 
sparse” (Brodie and Sills, 2011).
As for RP and side effects, there is evidence that add-
ing AEDs with the same MOAs may lead to an enhance-
ment of side effects. “In particular, care should be taken 
to avoid an excessive drug load, which can be associat-
ed with decreased tolerability” (Brodie and Sills, 2011).
 It is difficult to drawn reliable information from 
studies with AEDs with multiple MoAs given the fact 
that the same MoA might not be responsible for drug 
efficacy, or toxicity, in different patients. Furthermore, 
the mechanistic minutia of many available AEDs, with 
hypothetic contributions to their clinical effects, is still 
not fully understood. This brings more confusion to 
the concept of RP as it is mostly based on MoAs (Bro-
die and Sills, 2011).
Rational polytherapy. Reality?
Most patients with RE take two to three AEDs, some 
even four or more. Therefore, some rules should be in-
troduced to rationalise their use in order to achieve an 
optimal outcome. Can RP be a good strategy? In oth-
er words, is there evidence supporting RP? The correct 
response is no. So far, there is no evidence unequivo-
cally validating this form of polytherapy. Nonetheless, 
strong arguments favouring RP may be found.
According to Kwan and Brodie (2000a), in 2000, 64% 
of the patients with epilepsy de novo were achieving 
freedom from seizures with an appropriate monothera-
py regimen. Nine years later, this percentage increased 
by 4.4% (68.4%) through the use of and at the expense 
of polytherapy regimen (3, 4, and even 5 AEDs) with 
SGAEDs that had new or different MoAs (Brodie and 
Bamagous, 2009). Although small, this amount should 
not be disregarded when addressing RE, and it seems 
worthwhile considering polytherapy always using at 
least one SGAED.
Although sparse, there is experimental (Table 1) 
and clinical (Table 2) evidence in support of RP. Ani-
mal models of seizures, epilepsy and drug-related neu-
rotoxicity are ideal to evaluate the efficacy and toxic-
ity of drug combinations in large groups of genetical-
ly homogeneous animals. The latter is relevant even if 
direct transition from experimental data to humans is 
questionable (Barker-Haliski et al., 2014; Brodie and 
Sills, 2011). These studies should include: a) efficacy and 
toxicity models in which both AEDs are at least mini-
mally effective; b) AED ratios reflecting those used in 
clinical setting; c) concentration analysis of AEDs in 
both plasma and brain, in order to exclude confound-
ing pharmacokinetic interactions; and d) the use of ap-
propriate methods of analysis, such as isobolography, 
because they measure effectiveness and determine in-
fra-additive, additive, or supra-additive interactions 
(Brigo et al., 2013).
Some examples of experimental synergistic combina-
tions of AEDs will follow. The anticonvulsant interac-
tion between PB and PHT was found to be supradditive 
against maximal electroshock (MES) seizures in mice, 
but neurotoxicity was not studied (Masuda et al., 1981). 
Another combination, VPA and PHT, displayed syner-
References Synergistic combinations of AEDs
Masuda et al., 1981
Chez et al., 1994
Shank et al., 1994
Borowicz et al., 2002
Luszczki et al., 2003
Cuadrado et al., 2002
Luszczki et al., 2005 *
Shandra et al., 2013
Russmann et al., 2016
PB with PHT
VPA with PHT
TPM with CBZ and PB
GBP with CBZ, VPA, PHT and PB
LTG with TPM
VPA with LTG
TPM with FBM and OXC
LCM with CBZ, LTG, TPM, GBP and LEV
PER with ZNS
Table 1. Preclinical synergistic antiepileptic drug (AED) 
combinations
PB – Phenobarbital; PHT – Phenytoin; VPA – Valproate;  
CBZ – Carbamazepine; GBP – Gabapentin; LTG – Lamotrigine;  
TPM – Topiramate; FBM – Felbamate; OXC – Oxcarbazepine;  
LCM – Lacosamide; LEV – Levetiracetam; PER – Perampanel;  
ZNS – Zonisamide.
* Subadditivity (antagonism) regarding neurotoxicity with OXC and 
FBM or OXC and LTG.
Table 2. Clinical synergistic antiepileptic drug (AED) 
combinations
References Synergistic combinations of AEDs
Rowan et al., 1983
Leach, Brodie, 1994
Brodie, Yuen, 1997
Stephen et al., 1998
Pisani et al., 1999
Brodie, Munford, 1999
Perucca, 2006
Moeller et al., 2009
Chung et al., 2010
Flores et al., 2012
Brodie et al., 2014
VPA with ESM
VGB with TGB
VPA with LTG
LTG with TPM
VPA with LTG
CBZ with VGB or VPA
STP with CLB
VPA with LTG
LCM with LEV
LCM with AED sodium channel blockers
RTG with AED sodium channel 
blockers or AEDs with other MOAs
VPA – Valproate; LTG – Lamotrigine; ESM – Ethosuximide;  
CBZ – Carbamazepine; VGB – Vigabatrin; TGB – Tiagabin;  
TPM – Topiramate; LCM – Lacosamide; LEV – Levetiracetam;  
CLB – Clobazam; STP – Stiripentol; RTG – Retigabine.
José Pimentel, José Manuel Lopes Lima
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gism in terms of anticonvulsant effect against MES in 
the rodent and the neurotoxic activity was simple ad-
ditive (Chez et al., 1994). A clear-cut synergy was again 
evident against MES in mice when TPM was co-ad-
ministered with CBZ or PB (Shank et al., 1994). A dis-
tinct synergism also occurred for the combinations of 
gabapentin (GBP) with CBZ, VPA, PHT and PB (Boro-
wicz et al., 2002). Synergistic combination in terms of 
efficacy was shown between LTG and TPM (Luszczki 
et al., 2003), and TPM with felbamate (FBM) and OXC, 
but subadditivity or antagonism, with respect to neu-
rotoxicity with OXC and FBM or with OXC and LTG 
was also found in the MES-induced seizures and chim-
ney test in mice (Luszczki and Czuczwar, 2005). The 
same was found for LCM with CBZ, LTG, TPM, GBP 
and levetiracetam (LEV) in the 6-Hz seizure model in 
mice (Shandra et al., 2013).
Nevertheless, with the possible exception of the pre-
clinical synergistic interaction between VPA and LTG 
(Cuadrado et al., 2002), synergistic combinations identi-
fied in animal models do not reliable extend to the clin-
ic (Barker-Haliski et al., 2014). However, experimental 
studies may be the right way to overcome restrictions 
imposed by human clinical studies, such as fixed drug 
doses (which prevent optimal combinations of dosag-
es with the most benefit and least toxicity) (French and 
Faught, 2009). The first combinations with two AEDs 
with different MoAs, PB with PHT, proved to be supe-
rior in terms of efficacy and/or toxicity when compared 
to AEDs of similar MoAs, CBZ and PHT (Brigo et al., 
2013). These were the initial studies leading to the con-
cept of RP, which evolved with the advent of SGAEDs. 
Overall, every experimental study stresses the need to 
use a combined effect of two different pathways rath-
er than a single pharmacological pathway (Brigo et al., 
2013). Furthermore, the most successful experimen-
tal combination of two AEDs appears to be the one of 
a single MoA of one AED with a multiple MoAs of the 
other AED (Deckers et al., 2000). Recently, two wide-
ly used SGAEDs – perampanel (PER), a noncompeti-
tive AMPA receptor antagonist, and zonisamide (ZNS), 
a modulator of voltage-sensitive sodium channels and 
T-type calcium currents – have shown synergism in the 
rat amygdala kindling model of temporal lobe epilepsy. 
This suggests that these two AEDs could be success-
fully used in focal epilepsies (Russmann et al., 2016).
 Combinatorial clinical studies are difficult to un-
dertake. They require the investigation of efficacy and 
tolerability of both single AEDs and combinations in 
a homogeneous population of patients with a design 
powerful enough to be able to separate synergism from 
additivity alone. Moreover, they also need adjustments 
of the AEDs combinations to balance overall drug load 
(Barker-Haliski et al., 2014). The literature claims a par-
ticular efficacy for a combination of a sodium channel 
blocker with either a GABA-ergic (Brodie and Sills, 
2011) or a multiple MoAs drug (Kwan and Brodie, 
2000b). The only broad evidence of synergism is with 
VPA and LTG. This was achieved in a trial (Brodie and 
Yuen, 1997) in patients without seizure control, where 
an attempt was made to substitute CBZ, PHT or VPA 
for monotherapy LTG (and in which an adjustment in 
the LTG dosing schedules for the pharmacokinetic in-
teractions among these AEDs resulting in the same cir-
culating LTG concentrations for all three combinations 
was performed). The data has shown that the efficacy 
was strikingly higher in the VPA plus LTG group when 
compared with the LTG plus CBZ. Detailing a study 
that has already been mentioned, a trial performed in 
twenty patients with focal seizures stable on a combi-
nation of AEDs, showed that among the thirteen who 
did not display a good response to the consecutive ad-
dition of VPA and LTG, four became seizure free and 
another four experienced more than a 50% seizure re-
duction when both drugs were given in combination. 
This effect was achieved despite lower doses and circu-
lating concentrations than those occurring if adminis-
tered separately (Pisani et al., 1999).
Other apparent or proved synergistic combinations 
of AEDs with different MoAs, although based in small 
samples of patients, small clinical trials or short treat-
ment periods, are VPA with ethosuximide for gener-
alized absences (Rowan et al., 1983), PB with PHT for 
generalized tonic-clonic seizures (Cereghino et al., 
1975), CBZ with vigabatrin (VGB) or VPA (Walker and 
Koon, 1988; Kwan and Brodie, 2000a; Brodie and Mun-
ford, 1999), VGB with tiagabin (seldom used nowadays) 
for focal seizures (Leach and Brodie, 1994), LTG with 
TPM for a wide range of seizures (Stephen et al., 1998), 
stiripentol with clobazam in the severe myoclonic epi-
lepsies of the pediatric population (Perucca, 2006), and 
azogabine/retigabine with either sodium channel block-
ing AEDs or with AEDs with other MoAs (Brodie et al. 
2014), and LCM with any concomitant AED regimen, 
including sodium channel blocking AEDs (Chung et 
al., 2010). However, there is also evidence of a higher 
reduction in seizure frequency when LCM is associat-
ed to AEDs not acting on the sodium channel (Sake et 
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al., 2010). To investigate whether different MoAs-based 
AED combination therapies in focal epilepsies are more 
effective than same MoAs-based AEDs combinations, 
Margolis et al. (2014) used real-world data from a large 
sample and showed that the former combinations had 
greater effectiveness (as measured by treatment persis-
tence and lower risk for hospitalization or emergency 
department visits).
Finally, “irrational” polytherapy can occur due to 
several reasons and should be avoided (Brigo et al., 
2013). A wrong AED may be chosen for starting a mon-
otherapy regimen leading to an unfavourable event 
(such as an increase in seizures or toxic side effects). 
The solution is to replace the first AED by an appropri-
ate one, rather than adding yet another AED. Further-
more, an inadequate knowledge of the MoA of AEDs 
and their pharmacokinetic and or pharmacodynamic 
interactions between them may also lead to unexpect-
ed or unpleasant symptoms.
CONCLUSIONS
True role of RP in the treatment of the epilepsies is an 
ongoing topic. The offer of new AEDs with more fa-
vourable pharmacokinetic and pharmacodynamic pro-
files (but, importantly, new or different MoAs), has led 
to the use of this strategy in clinical practice as an op-
tion to increase efficacy. In fact, from the theoretical 
point of view, it is attractive to think in terms of RP. 
Although various experimental and clinical investiga-
tions have been undertaken, in general they lack robust-
ness and one must be cautions when attempting to ap-
ply the conclusions to clinical practice to bring about 
a synergic anticonvulsant effect in treating a specific 
epilepsy. However, it must be conceded that there are 
a few studies with conclusive evidence to support this 
strategy, the best documented suppradditive effect be-
ing the association of VPA and LTG for focal epilep-
sies. In addition, a greater effectiveness and a decrease 
of hospitalizations and emergency department visits 
seem able to be achieved with RP.
At present, RP must be considered as the use of 
available AEDs to treat seizures types and syndromes, 
some of unknown aetiology, using the available data 
of how they interact at the cellular level. Hence, one 
must admit this approach to be sub-optimal. Accord-
ingly, therapeutic strategy, including the choice of the 
best combination of AEDs, should be tailored to each 
patient. However, as a “rational” thought, RP is a strat-
egy worth attempting.
Concepts like efficacy, toxicity, synergism and ther-
apeutic index should be appreciated at the light of the 
paradigm used to assess drug effects. Further studies 
are needed and they should focus on: understanding 
the role of the MoAs in optimizing the control of ep-
ilepsies with polytherapy; identification of additional 
factors that may be crucial for the outcomes when this 
strategy is implemented, and to the knowledge of the 
underlying molecular aetiologies of seizures.
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